gebhart/patrepeval huggingface dataset:
Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. (1988)

Review of prognostic factors at Memorial Hospital in New York City has shown that adult patients with large-cell lymphoma (diffuse histiocytic lymphoma by Rappaport classification) who have high lactic dehydrogenase (LDH) and/or bulky mediastinal or abdominal disease are destined to do poorly with conventional combination chemotherapy, with a 2-year disease-free survival of about 20%. Patients who relapse after conventional combination chemotherapy have a similar poor prognosis. Thirty-one such patients with lymphoma were studied to evaluate the efficacy of intensive radiotherapy (hyperfractionated total body irradiation [TBI] [1,320 rad]), and cyclophosphamide (60 mg/kg/d for two days) followed by autologous bone marrow transplantation (ABMT). Our results show a disease-free survival advantage (P = .002) for 14 patients who underwent ABMT immediately after induction of remission with 79% surviving at a median follow-up 49.2+ months, compared with a median survival of 5.2 months for 17 patients administered ABMT while in relapse and/or after failing conventional treatment. Our results support the use of aggressive therapy as early treatment for patients with poor prognostic features.
Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells (1987)

We used a transfected L cell and a vaccinia vector carrying the herpes simplex virus type 1 (HSV-1) gene coding for glycoprotein D (gD) to characterize HSV-specific T-cell responses. Various studies with mice revealed that the vectors could stimulate some HSV-specific T-cell responses. Although the majority of the T cells contributing to the HSV-1 gD-specific proliferative response were of the Lyt-2.1+ phenotype, cytotoxic T cells (Tc), surprisingly, were not induced by these gD vectors. Even though gD appeared to be a target for a class II major histocompatibility complex (MHC)-restricted killer cell, neither gD vector was capable of forming a target cell complex which could be recognized by class I MHC-restricted HSV-specific Tc. Further investigation of the gD-specific responses revealed the presence of potent suppressor cells and factors capable of inhibiting HSV-specific Tc induction in in vitro assays. One interpretation of these data is that class I MHC-restricted HSV- and gD-specific Tc do not develop during HSV infection because of active suppression.
Frizzled-3Is Required for the Development of Major Fiber Tracts in the Rostral CNS (2002)

Many ligand/receptor families are known to contribute to axonal growth and targeting. Thus far, there have been no reports implicating Wnts and Frizzleds in this process, despite their large numbers and widespread expression within the CNS. In this study, we show that targeted deletion of the mouse fz3 gene leads to severe defects in several major axon tracts within the forebrain. In particular, fz3(-/-) mice show a complete loss of the thalamocortical, corticothalamic, and nigrostriatal tracts and of the anterior commissure, and they show a variable loss of the corpus callosum. Peripheral nerve fibers and major axon tracts in the more caudal regions of the CNS are mostly or completely unaffected. Cell proliferation in the ventricular zone and cell migration to the developing cortex proceed normally until at least embryonic day 14. Extensive cell death in the fz3(-/-) striatum occurs late in gestation, perhaps secondary to the nearly complete absence of long-range connections. In contrast, there is little cell death, as assayed by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling, in the cortex. These data provide the first link between Frizzled signaling and axonal development.
Successful Immunization of Humans with Irradiated Malaria Sporozoites: Humoral and Cellular Responses of the Protected Individuals (1991)

Two groups of volunteers were vaccinated by repeated exposure to the bites of Plasmodium falciparum-infected, x-irradiated mosquitoes in order to characterize the humoral and cellular immune responses of sporozoite-immunized, protected individuals. One of the two volunteers in the first immunization trial, when challenged by the bite of P. falciparum-infected mosquitoes, developed an infection only after a prolonged prepatent period. A second group of three volunteers who were exposed more frequently to larger numbers of infected mosquitoes irradiated with a lower x-ray dose was completely protected against sporozoite challenge. These individuals and the volunteer with delayed infection had high levels of antibodies to sporozoites and to the repeat region of the circumsporozoite (CS) protein. The CS-specific cellular immune responses of these volunteers were also stimulated by sporozoite immunization, as determined by proliferation of peripheral blood mononuclear cells (PBMC) and mitogen or antigen-expanded PBMC, in response to in vitro challenge with a recombinant P. falciparum CS protein. Based upon the assays used in this study, it is not possible to reach conclusions regarding specific immunologic responses and protection from sporozoite challenge.
Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies (2015)

Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects in healthy volunteers in two phase-1 studies. In study 1, healthy men received 50-, 100-, 150- or 225 mg and women received 100 mg JNJ-40411813 (n=6, each cohort) or placebo (n=2, each cohort) twice daily for seven days; smoking men (n=30) received placebo twice daily on days 1-7, 100 mg JNJ-40411813 (n=20) or placebo (n=10) on days 8-14. In study 2, healthy men received intravenous 0.005 mg/kg S(+) ketamine over 60 min at 3 (n=24; cohort 1), 12 h (n=8; cohort 3), and 24 h (n=8; cohort 2) after a single oral dose of 500 mg JNJ-40411813 or placebo. The pharmacokinetics and effects of JNJ-40411813 on cognition and subjective awareness were evaluated. Plasma JNJ-40411813 exposure was dose-dependent, t max ranged from 3-4 h and t 1/2 19.4-34.2 h across the dose levels. JNJ-40411813 significantly (p=0.02) reduced continuity of attention score (150 mg dose) and ameliorated smoking withdrawal-induced changes in power of attention and quality of episodic memory versus placebo. A modest reduction in alertness was observed at 150-225 mg doses, JNJ-40411813 (500 mg) reduced S(+) ketamine-induced negative symptoms by approximately 43% and 30% in cohorts 1 and 3, respectively. JNJ-40411813 was generally well-tolerated.
<title>PackBot: a versatile platform for military robotics</title> (2004)

The iRobot PackBot is a combat-tested, man-portable UGV that has been deployed in Afghanistan and Iraq. The PackBot is also a versatile platform for mobile robotics research and development that supports a wide range of payloads suitable for many different mission types. In this paper, we describe four R&D projects that developed experimental payloads and software using the PackBot platform. CHARS was a rapid development project to develop a chemical/radiation sensor for the PackBot. We developed the CHARS payload in six weeks and deployed it to Iraq to search for chemical and nuclear weapons. Griffon was a research project to develop a flying PackBot that combined the capabilities of a UGV and a UAV. We developed a Griffon prototype equipped with a steerable parafoil and gasoline-powered motor, and we completed successful flight tests including remote-controlled launch, ascent, cruising, descent, and landing. Valkyrie is an ongoing research and development project to develop a PackBot payload that will assist medics in retrieving casualties from the battlefield. Wayfarer is an applied research project to develop autonomous urban navigation capabilities for the PackBot using laser, stereo vision, GPS, and INS sensors.
Clinical and experimental evidence for persistentYersinia infection in reactive arthritis (1999)

The findings of bacterial antigens in the joint and persistent triggering infection elsewhere in the body are thought to be important in the pathogenesis of reactive arthritis (ReA). We describe a patient with clinical and laboratory features consistent with this. The initial presentation with erythema nodosum and periarthritis due to infection with Yersinia pseudotuberculosis IV was followed 13 months later by recurrent erythema nodosum with joint effusion. At that time, synovial fluid was shown to contain Yersinia antigens, and, surprisingly, Yersinia-specific 16S ribosomal RNA (rRNA) sequences were also identified by reverse transcriptase–polymerase chain reaction and sequencing. Since there was no serologic evidence of reinfection, we postulate that a silent persistent Yersinia infection was reactivated, leading to dissemination of organisms to the joint, with consequent induction of ReA. Although the finding of synovial Yersinia antigens years after the original infection in ReA has previously been reported, the presence of Yersinia 16S rRNA indicates that viable organisms were also able to reach the joint.
Cycloaddition of carbon dioxide to propylene oxide catalyzed by ionic liquids (2001)

In room temperature ionic liquids based on 1-n-butyl-3-methylimidazolium and n-butylpyridinium salts, cycloaddition of carbon dioxide to propylene oxide without any additional organic solvents has been investigated. It was found that 1-n-butyl-3-methylimidazolium tetrafluoroborate was the most active catalyst with almost 100% selectivity, and a suitable CO2–propylene oxide molar ratio was needed for high conversion. The ionic liquid used as catalyst for the reaction was recyclable.
Inhibitory Activities of (-)-Epigallocatechin-3-O-gallate against Topoisomerases I and II. (2001)

The substitution of gallic acid at the 3 position of (-)-epigallocatechin-3-O-gallate (EGCG) increased the inhibition against topoisomerase I from calf thymus gland and topoisomerase II from human placenta, and the substitution of a hydroxyl group at the 3' position increased the inhibition against the topoisomerase I. These results suggested that the 3 and 3' positions of the EGCG molecule play important roles in the process of inhibition of topoisomerases I and II. EGCG showed strong inhibition against topoisomerases I from wheat germ, calf thymus gland and Vero cells, and showed weak or no inhibition against topoisomerases I from carcinoma cells such as A549, HeLa and COLO 201 cells. EGCG differentially inhibited the topoisomerases I from different sources.
Monoclonal Antibodies That Recognize the Type-2 Activin Receptor, ACTR2 (1994)

Monoclonal antibodies (MAbs) were raised in mice against a bacterial fusion protein composed of the intracellular serine/threonine kinase domain of the type-2 activin receptor, ACTR2, fused to glutathione S-transferase. Three MAbs with high affinity toward the ACTR2 kinase domain were isolated, one of which recognized specifically ACTR2 expressed transiently in vascular endothelial cells. These reagents should be of use in the elucidation of mechanisms of transmembrane signaling by this member of the emerging receptor serine threonine kinase family.
Regulation of Plasma LDL-Cholesterol Levels by Dietary Cholesterol and Fatty Acids (1993)

Extensive data obtained in both experimental animals and humans demonstrate that steady-state plasma LDL-C concentrations are determined largely by the rate of LDL-C formation, Jt, and the level of LDL-R activity, Jm, located primarily in the liver. An increase in net cholesterol delivery to the liver suppresses Jm, slightly elevates Jt, and modestly raises the LDL-C level. Feeding lipids such as the 12:0, 14:0, and 16:0 saturated fatty acids further suppresses Jm, increases Jt, and markedly elevates the plasma LDL-C concentration. Feeding triacylglycerols containing the 18:1(c9) fatty acid restores hepatic receptor activity, decreases Jt, and modestly reduces the concentration of LDL-C in the plasma. The 18:2(c9, c12) compound has similar effects, although it is quantitatively less active than the monounsaturated fatty acid in restoring Jm. In contrast to these fatty acids that actively raise or lower hepatic receptor activity, a large group of compounds including the 4:0, 6:0, 8:0, 10:0, 18:0, and 18:1(t9) fatty acids have no demonstrable effect on any parameter of LDL-C metabolism. These fatty acids, therefore, can be added to animal and human diets with relative impunity. They will alter plasma LDL-C levels only to the extent that they replace the active saturated fatty acids (in which case they lower the LDL-C concentration) or unsaturated compounds (in which case they raise the plasma cholesterol level). All of these effects of cholesterol and the various fatty acids can be explained by the effects of these lipids in altering the size of the regulatory pool of cholesterol in the hepatocyte. However, many aspects of the cellular and molecular biology of these regulatory processes require additional investigation. In particular, new studies should focus on how the genetic background of an individual animal or human alters the quantitative response of its plasma LDL-C concentration to the dietary challenge of each of these types of lipids.
A Complete Microfluidic Screening Platform for Rational Protein Crystallization (2006)

We describe a complete microfluidic screening platform for protein crystallization that integrates fully programmable on-chip combinatorial mixing with dense assay storage using two-phase flows. This device supports rational crystallization strategies based on systematic solubility phase space mapping followed by nanoliter volume crystallization screening. Sequential formulation of arbitrary chemical mixtures and injection of nanoliter volume droplets into an immiscible carrier fluid creates a water/oil emulsion with independent control over droplet chemistry, size, frequency, and spacing. Long-term incubation of droplets with controlled dehydration is used to induce crystallization.
Aspirin--the first hundred years. (2000)

'Take two aspirin and call me in the morning', may be an old cliché deriding the medical profession, but the story of the first 100 years of aspirin suggests that this drug may be of benefit for a far greater range of ailments than those who synthesised it 100 years ago could have imagined.
Characterization of the Monoclonal Antibodies Against Human Protein C Specific for Calcium Ion-induced Conformers (1992)

Five Ca2+-dependent monoclonal antibodies against human protein C: HPC 1 to 5, have been produced. Calcium binding to the light chain (HPC 1, 2) or to the heavy chain (HPC 3, 4) elicited the epitopes for these antibodies. HPC 5 lost its binding activity upon disulfide bridge reduction. HPC 1 and 5 did not react with γ-carboxyglutamic acid (Gla)-domainless protein C nor with isolated Gla-domain while others retained the reactivity even after the Gla-domain had been removed. Half maximal binding of these antibodies were observed 0.35-1.5mM Ca2+. Other divalent cations including Mg2+ and Mn2+ could substitute for Ca2+. Thus the low affinity or secondary metal binding sites rather than the high affinity Ca2+-binding site may have participated in the epitope induction. Furthermore, HPC 1, 4 and 5 reacted with prothrombin and factor X. The cross-reactivities to prothrombin were lost in accordance with the extent of modification of the Gla residues, indicating that certain Gla-residues had been involved in the expression of conserved epitopes. It is notable that the conformational change in the Gla-domain also influenced the induction of a Ca2+-dependent epitope in the serine protease portion of the molecule (HPC 4). The antibodies did not affect the reactions in the fluid phase, but they, except HPC 2, interfered with the cell surface-mediated activation of protein C by the thrombin-thrombomodulin complex and inactivation of factor Va by activated protein C (APC). We therefore conclude that certain concerted conformational changes induced by Ca2+ in both the light and heavy chain of protein C are important for the functions of protein C on the surface of endothelial cells.
Modification of bacterial artificial chromosomes through Chi-stimulated homologous recombination and its application in zebrafish transgenesis (1998)

The modification of yeast artificial chromosomes through homologous recombination has become a useful genetic tool for studying gene function and enhancer/promoter activity. However, it is difficult to purify intact yeast artificial chromosome DNA at a concentration sufficient for many applications. Bacterial artificial chromosomes (BACs) are vectors that can accommodate large DNA fragments and can easily be purified as plasmid DNA. We report herein a simple procedure for modifying BACs through homologous recombination using a targeting construct containing properly situated Chi sites. To demonstrate a usage for this technique, we modified BAC clones containing the zebrafish GATA-2 genomic locus by replacing the first coding exon with the green fluorescent protein (GFP) reporter gene. Molecular analyses confirmed that the modification occurred without additional deletions or rearrangements of the BACs. Microinjection demonstrated that GATA-2 expression patterns can be recapitulated in living zebrafish embryos by using these GFP-modified GATA-2 BACs. Embryos microinjected with the modified BAC clones were less mosaic and had improved GFP expression in hematopoietic progenitor cells compared with smaller plasmid constructs. The precise modification of BACs through Chi-stimulated homologous recombination should be useful for studying gene function and regulation in cultured cells or organisms where gene transfer is applicable.
Drug Discovery: A Historical Perspective (2000)

Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.
Interacting with groups of computers (2003)

AUIs recognize human attention in order to respect and react to how users distribute their attention in technology-laden environments.
The Epithelial-to-Mesenchymal Transition in Cancer (2018)

The epithelial-to-mesenchymal transition (EMT) occurs during normal embryonic development, tissue regeneration, organ fibrosis, and wound healing.[...].
Remote Heart Rate Determination in RGB Data - An Investigation using Independent Component Analysis and Adaptive Filtering (2016)

An emerging topic in the field of elderly care is the determination and tracking of vital parameters, such as the heart rate. This parameter provides important information about a personâs current health status. Within the last years, various research focussed on this topic. The recognition of vital parameters is increasingly relevant for our ageing society. This paper presents a method to remotely determine the human heart rate with a camera. At this point, we suggest to use independent component analysis (ICA) and adaptive filtering for a robust detection. In our processing chain, we used different image processing techniques, e. g. face detection, and signal processing techniques, e. g. FFT and bandpass filtering, in this study. An evaluation with several probands, illuminations, frame rates and different heart rate levels showed that we could achieve a mean error of 4.36 BPM, which corresponds to CAND of 94.45 %, and a speed of 35 fps.
Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. (1987)

A panel of monoclonal antibodies (MAb) was generated against Chlamydia trachomatis serovar B, an etiologic agent of blinding trachoma. The specificities of MAb were determined by dot blot assay by using viable elementary bodies of 13 C. trachomatis serovars and two C. psittaci strains. The dot blot assay was used to identify those antigens that were unique and immunoaccessible on the chlamydial surface. MAb were identified that recognized bi-specific (serovars B and Ba) or subspecies-specific (various B complex serovars) surface-exposed antigenic determinants that were either resistant or sensitive to heat denaturation (56 degrees C, 30 min). All of the MAb recognized the major outer membrane protein as determined by either immunoblotting or radioimmunoprecipitation. MAb specific for immunoaccessible major outer membrane protein epitopes protected mice from toxic death after i.v. injection of B serovar elementary bodies and neutralized the infectivity of the organism for monkey eyes. In contrast, MAb reactive against non-immunoaccessible subspecies- or species-specific major outer membrane protein epitopes or against an immunoaccessible genus-specific epitope located on chlamydial lipopolysaccharide did not protect mice from toxic death or neutralize infectivity of the parasite for monkey eyes. These data suggest that those major outer membrane protein antigenic determinants that are serovar or serogroup specific and are accessible to antibody on the chlamydial cell surface may be useful as a recombinant subunit vaccine for trachoma.
Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. (1978)

Moloney leukemia virus activated both the classical and alternative pathways of human complement. About 500,000 virions were required to detect activation of the classical pathway whereas 5,000 times as many virions were necessary to initiate the alternative pathway, indicating that in this system only the former is of biological significance. Disruption of the virus with Triton X-100 destroyed its ability to initiate the alternative pathway without affecting its ability to activate the classical pathway. After ultracentrifugation of disrupted virus the active component could be recovered in the supernate and was isolated by isoelectric focusing in granulated gels. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic and analysis and cyanogen bromide digestion studies revealed that the activity resided in a methionine-containing protein having a pI of 7.5 and a molecular weight of approximately equal to 15,000 daltons. The purified protein interacts strongly with Clq and efficiently activates Cl. RNase and lipolytic enzymes had no effect on the isolated protein but incubation with trypsin resulted in loss of activity. Enzymatic digestion studies of surface-labeled virus indicate that the active protein is a viral membrane protein. On the basis of these results it is concluded that the complement receptor of Moloney leukemia virus is the surface protein p15E.
Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A) (1999)

ISIS 5132 is well tolerated at doses up to 6.0 mg/kg when administered as a thrice weekly 2-hour infusion for 3 consecutive weeks. The pharmacokinetic behavior of the drug is reproducible, and suppression of target gene expression is observed in circulating PBMCs.